Recombinant IL6R (Satralizumab Biosimilar) antibody

Catalog No. ABIN7488088

The Mammalian Cells Monoclonal anti-IL6R (Satralizumab Biosimilar) antibody has been validated for ELISA. It is suitable to detect IL6R (Satralizumab Biosimilar) in samples from Human.

Quick Overview for Recombinant IL6R (Satralizumab Biosimilar) antibody (ABIN7488088)

Target: IL6R (Satralizumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mammalian Cells

Clonality: Monoclonal

Conjugate: This IL6R (Satralizumab Biosimilar) antibody is un-conjugated

Application: ELISA

Grade: Research Grade

Product Details anti-IL6R (Satralizumab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Satralizumab Biosimilar - Anti-IL6R mAb

Characteristics: Antibody Type: IgG2-kappa

Purification: Recombinant antibody expressed in mammalien cells and purified.

Isotype: IgG2 kappa

Application Details

Restrictions: For Research Use only

Handling

Buffer: PBS pH 7.5

Storage: -80 °C

Storage Comment: store at -80°C

Target Details for IL6R (Satralizumab Biosimilar)

Target: IL6R (Satralizumab Biosimilar)

Target Type: Biosimilar

Background: SA-237
Satralizumab (SA237), a humanized IgG2 targeting interleukin-6 (IL-6) receptor (IL-6R).

CAS-No: 1535963-91-7